Business
Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
MONTPELLIER, France, September 17, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its half-year 2025 results, provided a corporate update and announced the availability of the half-year report.
About this update from Sensorion Sas
[{"type":"list","items":[{"val":[{"type":"text","content":"Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene","length":270,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Positive initial safety profile reported in all six patients treated so far","length":75,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests","length":153,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025","length":124,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":352,"olType":false}]},{"val":[{"type":"text","content":"GJB2-GT on track for first CTA filing in Q1 2026; Regulatory dossier to be supported by discussions with FDA and EMA in Q3 2025; GJB2-GT program addresses pediatric congenital deafness, progressive forms of hearing loss in children, and early onset of presbycusis in adults","length":273,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Completed enrollment in SENS-401’s Phase 2a Proof of Concept study in Cisplatin-Induced Ototoxicity (NOTOXIS) with topline data expected to be reported by the end of H2 2025","length":173,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash and short-term deposits of €57.1m finance the Company into Q3 2026","length":71,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1139,"olType":false},{"type":"text","content":"MONTPELLIER, France, September 17, 2025--(BUSINESS WIRE)--Regulatory News:","length":74,"tagName":"p"},{"type":"text","content":"Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its half-year 2025 results, provided a corporate update and announced the availability of the half-year report.","length":314,"tagName":"p"},{"type":"text","content":"&q...